HSBC initiates coverage on Fujian Wanchen stock with Buy rating

HSBC has initiated coverage on Fujian Wanchen Biotechnology Group (SZ:300972) with a Buy rating and a price target of RMB204.30. The firm projects robust growth, forecasting a 95% net profit compound annual growth rate and 32% revenue compound annual growth rate between 2024 and 2027, driven primarily by the planned launch of 7,500 new franchise stores, alongside anticipated improvements in same-store sales and operational margins.

Analysis

HSBC has initiated coverage on Fujian Wanchen Biotechnology Group (SZ:300972) with a 'Buy' rating and a price target of RMB204.30, signaling strong institutional confidence. The bullish thesis is anchored on an aggressive expansion strategy, with HSBC forecasting the launch of 7,500 new franchise stores over the next three years, including a particularly ambitious 4,000 new locations in 2025. This rapid physical footprint expansion is projected to fuel a 32% revenue compound annual growth rate (CAGR) from 2024 to 2027. More significantly, profitability is expected to outpace revenue growth, with a projected 95% net profit CAGR over the same period. This margin expansion is anticipated to stem from improved operational efficiencies due to economies of scale and an increasing sales contribution from higher-margin self-owned brands and private labels, complementing expected growth in same-store sales.

Key Decisions for Investors

• Investors with a high-risk, high-growth appetite should consider the 'Buy' rating and substantial growth forecasts as a signal for a potential long position, as the thesis presents a clear path to significant value creation.
• The primary execution risk is the aggressive store rollout; therefore, investors must closely monitor company reports on new store openings against HSBC's forecast, especially the 4,000-store target for 2025.
• Beyond store count, it is crucial to track same-store sales growth and gross margin trends, as improvements in these metrics are essential for achieving the projected 95% net profit CAGR and validating the long-term investment case.